Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy Hughes

Showing results (131-140 of 146) with videos related to

Pageof 15
Sort By:
Cancer|April 8, 2017
Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutationFranck E Nicolini, Grzegorz W Basak, Dong-Wook Kim, et al.
Blood|March 9, 2006
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing resultsTimothy Hughes, Michael Deininger, Andreas Hochhaus, et al.
Research Square|July 28, 2023
Multi-ancestry epigenome-wide analyses identify methylated sites associated with aortic augmentation index in TOPMed MESAAni Manichaikul, Xiaowei Hu, Jeongok Logan, et al.
Hypertension (Dallas, Tex. : 1979)|February 11, 2026
Factors Associated With Discordant Blood Pressure Measures among Very Old Adults: Results From the Atherosclerosis Risk in Communities (ARIC) StudyFredrick Larbi Kwapong, Benjamin Grobman, Hannah Col, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2008
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemiaNeil P Shah, Hagop M Kantarjian, Dong-Wook Kim, et al.
British Journal of Haematology|December 23, 2025
The PINNACLE study: A multicentre phase II trial of nilotinib in combination with pegylated interferon-α2b in newly diagnosed chronic phase chronic myeloid leukaemiaDavid T Yeung, Andrew P Grigg, John Reynolds, et al.
NEJM AI|April 9, 2026
Brain Health from Sleep EEG: A Multicohort, Deep Learning Biomarker for Cognition, Disease, and MortalityWolfgang Ganglberger, Haoqi Sun, Niels Turley, et al.
Blood|December 1, 2007
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemiaPhilipp le Coutre, Oliver G Ottmann, Francis Giles, et al.
The New England Journal of Medicine|March 15, 2003
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemiaStephen G O'Brien, François Guilhot, Richard A Larson, et al.
Translational Psychiatry|October 10, 2018
Elevated expression of a minor isoform of ANK3 is a risk factor for bipolar disorderTimothy Hughes, Ida E Sønderby, Tatiana Polushina, et al.
Pageof 15

Showing results (131-140 of 146) with videos related to

Sort By:
Pageof 15
Cancer|April 8, 2017
Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutationFranck E Nicolini, Grzegorz W Basak, Dong-Wook Kim, et al.
Blood|March 9, 2006
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing resultsTimothy Hughes, Michael Deininger, Andreas Hochhaus, et al.
Research Square|July 28, 2023
Multi-ancestry epigenome-wide analyses identify methylated sites associated with aortic augmentation index in TOPMed MESAAni Manichaikul, Xiaowei Hu, Jeongok Logan, et al.
Hypertension (Dallas, Tex. : 1979)|February 11, 2026
Factors Associated With Discordant Blood Pressure Measures among Very Old Adults: Results From the Atherosclerosis Risk in Communities (ARIC) StudyFredrick Larbi Kwapong, Benjamin Grobman, Hannah Col, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2008
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemiaNeil P Shah, Hagop M Kantarjian, Dong-Wook Kim, et al.
British Journal of Haematology|December 23, 2025
The PINNACLE study: A multicentre phase II trial of nilotinib in combination with pegylated interferon-α2b in newly diagnosed chronic phase chronic myeloid leukaemiaDavid T Yeung, Andrew P Grigg, John Reynolds, et al.
NEJM AI|April 9, 2026
Brain Health from Sleep EEG: A Multicohort, Deep Learning Biomarker for Cognition, Disease, and MortalityWolfgang Ganglberger, Haoqi Sun, Niels Turley, et al.
Blood|December 1, 2007
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemiaPhilipp le Coutre, Oliver G Ottmann, Francis Giles, et al.
The New England Journal of Medicine|March 15, 2003
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemiaStephen G O'Brien, François Guilhot, Richard A Larson, et al.
Translational Psychiatry|October 10, 2018
Elevated expression of a minor isoform of ANK3 is a risk factor for bipolar disorderTimothy Hughes, Ida E Sønderby, Tatiana Polushina, et al.
Pageof 15